For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
13
views
36
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      181
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Survival outcomes of patients with head and neck squamous cell cancer with hepatitis B virus infection: An analysis from an endemic tertiary center

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Hepatitis B virus (HBV) affects the occurrence and survival outcome of various malignant disorders. The study aimed to evaluate the survival outcome of head and neck squamous cell cancer (HNSCC) patients with or without HBV infection.

          Methods

          This study included patients with HNSCC who visited Taichung Veterans General Hospital from 2007 to 2015. HBV infection was defined by hepatitis B surface antigen (HBsAg) seropositivity. By propensity score matching, we compared survival outcomes, including progression‐free survival (PFS) and overall survival (OS), among patients with or without HBV infection.

          Results

          The prevalence of HBV infection in our cohort was 12.3%. Among the 1,015 patients included in the matched analysis, a higher risk of baseline liver cirrhosis (11.3% vs. 3.4%, p < 0.001) and initial hepatic dysfunction (10.8% vs. 5.4%, p = 0.005) rates were observed than those without HBV infection at baseline. The 5‐year OS was 43.1% and 53.2% ( p < 0.001) and the 5‐year PFS was 37.4% and 42.3% ( p = 0.007) in patients with and without HBV infection, respectively. The incidence of subsequent hepatic dysfunction showed no difference between patients with and without HBV infection (29.6% vs. 26.8%, p = 0.439).

          Conclusions

          Patients with HNSCC and HBV infection were younger and had a higher risk of cirrhosis compared to those without HBV infection. Moreover, HBV infection significantly influenced the OS and PFS outcomes but not subsequent hepatic dysfunction in patients with HNSCC.

          Abstract

          5‐year overall survival in hepatitis B surface antigen (HBsAg)‐positive and HBsAg‐negative patients with head and neck squamous cell carcinoma (HNSCC).

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

          Robert Ferris, George Blumenschein, Jérôme Fayette … (2016)
          Background Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition. Methods In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy to receive nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks or standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was overall survival. Additional end points included progression-free survival, rate of objective response, safety, and patient-reported quality of life. Results The median overall survival was 7.5 months (95% confidence interval [CI], 5.5 to 9.1) in the nivolumab group versus 5.1 months (95% CI, 4.0 to 6.0) in the group that received standard therapy. Overall survival was significantly longer with nivolumab than with standard therapy (hazard ratio for death, 0.70; 97.73% CI, 0.51 to 0.96; P=0.01), and the estimates of the 1-year survival rate were approximately 19 percentage points higher with nivolumab than with standard therapy (36.0% vs. 16.6%). The median progression-free survival was 2.0 months (95% CI, 1.9 to 2.1) with nivolumab versus 2.3 months (95% CI, 1.9 to 3.1) with standard therapy (hazard ratio for disease progression or death, 0.89; 95% CI, 0.70 to 1.13; P=0.32). The rate of progression-free survival at 6 months was 19.7% with nivolumab versus 9.9% with standard therapy. The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group. Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group. Physical, role, and social functioning was stable in the nivolumab group, whereas it was meaningfully worse in the standard-therapy group. Conclusions Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy. (Funded by Bristol-Myers Squibb; CheckMate 141 ClinicalTrials.gov number, NCT02105636 .).
          Article 0 comments Cited 1192 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

            Norah Terrault, Anna Lok, Brian McMahon … (2018)
            Article 0 comments Cited 977 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

              Barbara Burtness, Kevin Harrington, Richard Greil … (2019)
              Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response.
              Article 0 comments Cited 923 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Cheng‐Wei Chou:
                ORCID: https://orcid.org/0000-0003-1801-4964
                ccwei@vghtc.gov.tw
                Journal
                Journal ID (nlm-ta): Cancer Med
                Journal ID (iso-abbrev): Cancer Med
                Journal ID (doi): 10.1002/(ISSN)2045-7634
                Journal ID (publisher-id): CAM4
                Title: Cancer Medicine
                Publisher: John Wiley and Sons Inc. (Hoboken )
                ISSN (Electronic): 2045-7634
                Publication date (Electronic): 24 November 2022
                Publication date Collection: March 2023
                Volume: 12
                Issue: 6 ( doiID: 10.1002/cam4.v12.6 )
                Pages: 6802-6810
                Affiliations
                [ 1 ] Division of Hematology/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan
                [ 2 ] Department of Post‐Baccalaureate Medicine, College of Medicine National Chung Hsing University Taipei Taiwan
                [ 3 ] School of Medicine National Yang Ming Chiao Tung University Taichung Taiwan
                [ 4 ] School of Speech Language Pathology & Audiology Chung Shan Medical University Taichung Taiwan
                [ 5 ] Department of Audiology and Speech‐Language Pathology Asia University Taichung Taiwan
                [ 6 ] Department of Otolaryngology‐Head & Neck Surgery Taichung Veterans General Hospital Taichung Taiwan
                [ 7 ] Department of Life Science Tunghai University Taichung Taiwan
                [ 8 ] School of Medicine Chung Shan Medical University Taichung Taiwan
                [ 9 ] Graduate Institute of Biomedical Sciences China Medical University Taichung Taiwan
                Author notes
                [*] [* ] Correspondence

                Cheng‐Wei Chou, MD, Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, Taiwan 40705, ROC.

                Email: ccwei@ 123456vghtc.gov.tw

                Author information
                https://orcid.org/0000-0002-5934-724X
                https://orcid.org/0000-0001-9744-0368
                https://orcid.org/0000-0003-1801-4964
                Article
                Publisher ID: CAM45469 Other ID: CAM4-2022-07-2895.R1
                DOI: 10.1002/cam4.5469
                PMC ID: 10067106
                PubMed ID: 36426417
                SO-VID: 488492dc-b1ec-4314-9fa5-395d86e98e02
                Copyright © © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
                License:

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                Date revision received : 30 October 2022
                Date received : 24 July 2022
                Date accepted : 13 November 2022
                Page count
                Figures: 3, Tables: 5, Pages: 9, Words: 5081
                Funding
                Funded by: Taichung Veterans General Hospital , doi 10.13039/501100010101;
                Award ID: TCVGH‐1113702B
                Award ID: TCVGH‐NHRI111007
                Funded by: Research and Development , doi 10.13039/100006190;
                Categories
                Subject: Research Article
                Subject: RESEARCH ARTICLES
                Subject: Clinical Cancer Research
                Custom metadata
                source-schema-version-number 2.0
                cover-date March 2023
                details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.7 mode:remove_FC converted:02.04.2023

                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: cirrhosis,head and neck squamous cell cancer (hnscc),hepatic dysfunction,hepatitis b virus (hbv),immune checkpoint inhibitor (ici),survival
                Data availability:
                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: cirrhosis, head and neck squamous cell cancer (hnscc), hepatic dysfunction, hepatitis b virus (hbv), immune checkpoint inhibitor (ici), survival

                Comments

                Comment on this article

                scite_

                Similar content181

                See all similar

                Cited by1

                See all cited by

                Most referenced authors918

                See all reference authors